TY - JOUR T1 - Review: available evidence does not support the use of β blockers as first line treatment for hypertension JF - Evidence Based Medicine JO - Evid Based Med SP - 112 LP - 112 DO - 10.1136/ebm.12.4.112 VL - 12 IS - 4 A2 - , Y1 - 2007/08/01 UR - http://ebm.bmj.com/content/12/4/112.abstract N2 - Wiysonge C, Bradley H, Mayosi B, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;(1):CD002003.OpenUrlPubMed 
 
 Q In adults with hypertension, what is the effectiveness and safety of β blockers (BBs)? Clinical impact ratings GP/FP/Primary care ★★★★★★★ IM/Ambulatory care ★★★★★★☆ Nephrology ★★★★★★☆ Cardiology ★★★★★☆☆ Data sources: PubMed, EMBASE/Excerpta Medica, Cochrane Database of Systematic Reviews, Cochrane Register of Controlled Trials, York Database of Abstracts and Reviews of Effectiveness, reference lists, experts in the field, and drug manufacturers. Study selection and assessment: randomised controlled trials (RCTs) that evaluated BBs in adults with hypertension. Study methods were assessed for quality, including allocation concealment, blinding, and completeness of follow up. 13 RCTs (91 561 patients) met the selection criteria. Outcomes: total mortality. Secondary outcomes included coronary heart disease, cardiovascular disease, stroke, and adverse drug reactions. BBs do not reduce mortality (table) or coronary heart disease (see table at www.evidence-basedmedicine.com) more than placebo, diuretics, or renin angiotensin system … ER -